**Methods**

**Study design and setting**

We conducted a retrospective cohort study between March 23 and May 10, 2020, on all subjects screened for the COVID-19 within the UDACS (*Unité de Dépistage Ambulatoire du COVID-19 Sud*) of Saint-Pierre, one of the two SARS-CoV-2 testing centers of the *Centre Hospitalier Universitaire Réunion* (CHU). When SARS-CoV-2 emerged on the island, the dengue epidemic was already burgeoning, the UDACS was placed in the second line of the reception system for COVID-19 patients, the frontline being the emergency units and the dedicated hospital for COVID-19 patients, the CHUFélix Guyon, located in Saint-Denis, whereby are the prefecture and the international airport.

**Ethics statement**

Outpatients presenting consecutively at the SARS-CoV-2 testing center were informed of the study orally and by means of an information sheet. People who expressed no opposition were asked to answer a questionnaire and surveyed in face-to-face by a nurse, in accordance to the French legislation on bioethics for retrospective researches. Patient’s medical records were retrospectively reviewed, and de-identified data were collected in standardized forms according the MR-004 procedure of the *Commission Nationale de l’Informatique et des Libertés* (the French information protection commission). The ethical character of this study on previously collected data was approved by the Scientific Committee for COVID-19 research of the CHU Réunion and de-identified data were registered on the Health Data Hub.

**Data collection**

The items of the questionnaire included information on demographics (gender, age), occupation, risk factors (smoking, obesity, recent travel abroad < 15 days), comorbidities (diabetes, hypertension, cardiovascular disease, chronic obstructive pulmonary disease, cancer, previous episode of dengue, other), intra-household and individual exposure to SARS-CoV-2, individual symptoms (fever, cough, dyspnea/shortness of breath, body ache, diarrhea, nausea, vomiting, dyspepsia, eructation, abdominal pain, ageusia, dysgeusia/metallic taste, anosmia, fatigue, headache, retro-orbital pain, sore throat, runny nose, nasal congestion, sneezing) and treatment (antihypertensive drugs, hydroxychloroquine). Temperature, pulse rate, respiratory rate and oxygen saturation (SpO2) were measured upon the consultation, as well as the presence of cough and anxiety. People reporting symptoms were physically examined by a resident and further by a senior infectious disease doctor, according to routine care procedures.

**Diagnostic procedures**

All the attendees were screened for SARS-CoV-2 using a nasopharyngeal swab inserted and held in one nostril for about twenty seconds [1]. The sample was processed for a SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) using a Microlab NIMBUS/STARlet IVD (Seegene, Seoul, Republic of Korea) or a MagNa Pure Compact® (Roche Life Science, Penzberg, Germany) automaton for nucleic acid extraction. SARS-CoV-2 ribonucleic acid sequences were identified using the Allplex 2019-nCovTM assay (Seegene, Seoul, Republic of Korea) or an in-house kit (CNR Pasteur), targeting N, RdRP and E genes, or N and IP2/IP4 targets of RdRP, respectively. SARS-CoV-2 genome sequences were amplified using a Bio-Rad CFX96® (BioRad, Hercules, CA, USA) or a LightCycler 480®(Roche Diagnostics, Basel, Switzerland) system. In addition, each patient suspected of dengue was tested for NS1 antigen using an OnSiteTM Duo dengue Ag-IgG-IgM rapid diagnostic test (CTK Biotech, San Diego, CA, USA) and if negative further explored with a DENV RT-PCR (NucliSens easyMAG, Biomerieux®, France; LightCycler 480®, Roche Dagnostics, Basel, Switzerland) or a Panbio® dengue Duo (IgM/IgG) capture ELISA (Abbott, Chicago, IL, USA) according to the timing of symptoms. People without symptoms were excluded from the study. Patients requiring hospitalization were transferred promptly from the UDACS to the COVID-19 units.

**Statistical analysis**

Given the research purpose, co-infections at clinical presentation were excluded from the analysis. Proportions between non COVID-19 and non-dengue other febrile illnesses (OFIs), COVID-19 and dengue subjects were compared using Chi square or Fisher exact tests, as appropriate.

Univariable and multivariable multinomial logistic regression models were fitted within Stata14® (College Station, Texas, USA) to identify independent predictors of COVID-19 and dengue, taking OFIs as controls. At the first step, we fitted a full multinomial logistic regression model with all significant variables identified by univariable analysis. From these covariates, we used a backward stepwise selection procedure to drop out non-significant variables (output if P value > 0.05). At the second step, we built a minimal multinomial logistic regression model with all significant covariates from the precedent model plus age.

We next performed weighed analyses on the overall inverse probability of hospitalization to assess the potential for selection bias. Briefly, we applied in logistic regression models the hospitalization rates observed for confirmed COVID-19 and dengue cases over the study period, the actual rate (1.8%) or a probability 16% for OFIs using the *svy* function in Stata.

To limit the potential for misclassification bias in the differential diagnosis between COVID-19 and dengue due to the overlapping symptoms between COVID-19 and OFIs, we also performed a sensitivity analysis restricted to confirmed COVID-19 and dengue cases *(i.e.*, excluding OFIs).

Crude and adjusted Odds ratios (OR) and 95% Confidence Intervals (95%CI) were assessed using the binomial and Cornfield methods, respectively. All interaction terms between the variables were tested. The likelihood of the models was tested using the Bayesian Information (BIC) criterion using the *fitstat* module [2]. The adequacy of the models was tested using the modified Hosmer and Lemeshow goodness of fit test for multinomial regression using the *mlogitgof* command [3]. The discriminatory performance of the models for the diagnosis of COVID-19 and dengue was tested using the areas under the receiver operating characteristics (ROC) curves.

For all these analyses, observations with missing data were ruled out and a *P*-value less than 0.05 was considered as statistically significant.

**References**

1. Marty FM, Chen K, Verrill KA. How to obtain a nasopharyngeal swab specimen. New Engl J Med 2020; 382; e76. <https://dx.doi/>10.1056/NEJMvcm2010260.
2. Long JS, Freese J. Scalar measures of fit for regression models. Indiana University and University of Wisconsin-Madison press. 2000; 1-9 pp. https://fmwww.bc.edu/repec/bocode/fitstat.pdf
3. Fagerland MW, Hosmer DW. A generalized Hosmer-Lemeshow goodness-of-fit test for multinomial logistic regression models. Stata Journal 2012; 12(3): 447-53. <https://dx.doi/>10.1177/1536867X1201200307.